ACP 01

Drug Profile

ACP 01

Alternative Names: ACP-01; Angiogenic Cell Precursors - Hemostemix; Endothelial progenitor cells - Hemostemix; VesCell

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TheraVitae
  • Developer Hemostemix; Mahidol University; TheraVitae
  • Class Anti-ischaemics; Heart failure therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Peripheral arterial disorders; Thromboangiitis obliterans
  • No development reported Angina pectoris; Cardiomyopathies; Heart failure

Most Recent Events

  • 24 Sep 2018 Hemostemix plans to submit pre-IND application to USFDA for heart-disorders before the end of the 4th quarter for 2018
  • 24 Sep 2018 Hemostemix plans a clinical trial for Heart-disorders
  • 30 May 2018 Hemostemix initiates enrolment in a phase II trial for Peripheral arterial disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top